GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Forward Dividend Yield %

Royalty Pharma (Royalty Pharma) Forward Dividend Yield %

: 2.98% (As of Today)
View and export this data going back to 2020. Start your Free Trial

As of today (2024-04-16), the Forward Annual Dividend Yield of Royalty Pharma is 2.98%.

As of today (2024-04-16), the Trailing Annual Dividend Yield of Royalty Pharma is 2.86%.

RPRX's Forward Dividend Yield % is ranked better than
74% of 150 companies
in the Biotechnology industry
Industry Median: 1.595 vs RPRX: 2.98

Royalty Pharma's Dividends per Share for the three months ended in Dec. 2023 was $0.20.

During the past 12 months, Royalty Pharma's average Dividends Per Share Growth Rate was 5.30% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 38.70% per year.

During the past 7 years, the highest 3-Year average Dividends Per Share Growth Rate of Royalty Pharma was 38.70% per year. The lowest was 38.70% per year. And the median was 38.70% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison

For the Biotechnology subindustry, Royalty Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma Forward Dividend Yield % Distribution

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Forward Dividend Yield % falls into.



Royalty Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Royalty Pharma Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
USD 0.2102024-02-152024-02-162024-03-15Cash DividendquarterlyUSD:USD 1.000000
USD 0.2002023-11-162023-11-172023-12-15Cash DividendquarterlyUSD:USD 1.000000
USD 0.2002023-08-172023-08-182023-09-15Cash DividendquarterlyUSD:USD 1.000000
USD 0.2002023-05-182023-05-192023-06-15Cash DividendquarterlyUSD:USD 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Royalty Pharma's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=0.84/28.25
=2.97 %

Current Share Price is $28.25.
Royalty Pharma's Dividends per Share for the forward twelve months is calculated as $0.21 * 4 = $0.84.

Royalty Pharma's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=0.81/28.25
=2.87 %

Current Share Price is $28.25.
Royalty Pharma's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Royalty Pharma  (NAS:RPRX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Royalty Pharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma (Royalty Pharma) Business Description

Traded in Other Exchanges
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Executives
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne officer: EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta director, officer: CEO, Chairman of the Board 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd officer: EVP, Investments & GC C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani director, 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic 10 percent owner C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a. 10 percent owner 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert director 110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez director MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080